281 related articles for article (PubMed ID: 26350436)
41. New insights into the FGF23-Klotho axis.
Olauson H; Vervloet MG; Cozzolino M; Massy ZA; Ureña Torres P; Larsson TE
Semin Nephrol; 2014 Nov; 34(6):586-97. PubMed ID: 25498378
[TBL] [Abstract][Full Text] [Related]
42. Fibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease.
Harjes LM; Parker VJ; Dembek K; Young GS; Giovaninni LH; Kogika MM; Chew DJ; Toribio RE
J Vet Intern Med; 2017 May; 31(3):784-790. PubMed ID: 28419560
[TBL] [Abstract][Full Text] [Related]
43. Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review.
Summers S; Michael HT; Szlosek D; Mack R
J Feline Med Surg; 2024 Apr; 26(4):1098612X241234984. PubMed ID: 38682929
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
Courbon G; Martinez-Calle M; David V
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
[TBL] [Abstract][Full Text] [Related]
45. Acid Load and Phosphorus Homeostasis in CKD.
Khairallah P; Isakova T; Asplin J; Hamm L; Dobre M; Rahman M; Sharma K; Leonard M; Miller E; Jaar B; Brecklin C; Yang W; Wang X; Feldman H; Wolf M; Scialla JJ;
Am J Kidney Dis; 2017 Oct; 70(4):541-550. PubMed ID: 28645705
[TBL] [Abstract][Full Text] [Related]
46. Deleterious effects of phosphate on vascular and endothelial function via disruption to the nitric oxide pathway.
Stevens KK; Denby L; Patel RK; Mark PB; Kettlewell S; Smith GL; Clancy MJ; Delles C; Jardine AG
Nephrol Dial Transplant; 2017 Oct; 32(10):1617-1627. PubMed ID: 27448672
[TBL] [Abstract][Full Text] [Related]
47. [Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease].
Dzgoeva FU; Sopoev MY; Gatagonova TM; Bestaeva TL; Khamitsaeva OV
Ter Arkh; 2015; 87(6):68-74. PubMed ID: 26281199
[TBL] [Abstract][Full Text] [Related]
48. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study.
Yasin A; Liu D; Chau L; Madrenas J; Filler G
BMC Nephrol; 2013 Feb; 14():39. PubMed ID: 23413976
[TBL] [Abstract][Full Text] [Related]
49. [Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].
Dzgoeva FU; Gatagonova TM; Bestaeva TL; Sopoev MIu; Bazaeva BG; Khamitsaeva OV
Ter Arkh; 2014; 86(6):63-9. PubMed ID: 25095658
[TBL] [Abstract][Full Text] [Related]
50. [Clinical aspect of recent progress in phosphate metabolism. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23)].
Endo I
Clin Calcium; 2009 Jun; 19(6):815-20. PubMed ID: 19483276
[TBL] [Abstract][Full Text] [Related]
51. [Clinical aspect of recent progress in phosphate metabolism. Phosphate retension, a powerful risk factor for mortality in chronic kidney disease (CKD)].
Imanishi Y
Clin Calcium; 2009 Jun; 19(6):828-35. PubMed ID: 19483278
[TBL] [Abstract][Full Text] [Related]
52. The challenge of controlling phosphorus in chronic kidney disease.
Cannata-Andía JB; Martin KJ
Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
[TBL] [Abstract][Full Text] [Related]
53. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
[TBL] [Abstract][Full Text] [Related]
54. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
55. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
[TBL] [Abstract][Full Text] [Related]
56. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
[TBL] [Abstract][Full Text] [Related]
57. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
58. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
Muras K; Masajtis-Zagajewska A; Nowicki M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
[TBL] [Abstract][Full Text] [Related]
59. Sodium phosphate cotransporter 2a inhibitors: potential therapeutic uses.
Xue J; Thomas L; Dominguez Rieg JA; Rieg T
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):486-492. PubMed ID: 35894284
[TBL] [Abstract][Full Text] [Related]
60. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)
Kritmetapak K; Losbanos L; Berent TE; Ashrafzadeh-Kian SL; Algeciras-Schimnich A; Hines JM; Singh RJ; Kumar R
BMC Nephrol; 2021 Mar; 22(1):114. PubMed ID: 33784965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
